Roche: CHMP favourable opinion for Covid-19 drug
(CercleFinance.com) - Roche has confirmed that the EMA CHMP has issued a scientific opinion supporting the use of the investigational casirivimab-imdevimab antibody cocktail as a treatment option for patients with mild-to-moderate Covid-19.
The CHMP's scientific opinion assists national decision-making in EU states on the use of the antibodies before formal authorisation is granted in the event of a public health emergency.
Roche and Regeneron are working together in the development and manufacture of the antibody cocktail. The Swiss healthcare group will be responsible for distribution in Europe and other countries outside the United States.
Copyright (c) 2021 CercleFinance.com. All rights reserved.